Comparison of demographic data between patients with elevated or normal PRL levels
| Factors | Elevated PRL RIS/OLZ (n=155/n=58) | Normal PRL RIS/OLZ (n=109/n=117) | Statistics RIS/OLZ | P values RIS/OLZ |
| Age, years | 49 (32, 58)/34 (27, 47) | 43 (29.25, 55)/38 (24, 50.25) | U=−1.68/0.21 | 0.093/0.834 |
| Gender/female, number (%) | 82 (52.90)/47 (81.03) | 40 (36.70)/62 (52.99) | χ2=6.76/12.98 | 0.009*/<0.001* |
| Illness duration, years | 16.50 (6.75, 31)/7 (1, 16) | 13 (6, 24)/4.32 (1, 19.82) | U=−1.29/0.34 | 0.197/0.733 |
| Age of onset, years | 26 (20.75, 30.25)/25 (20.50, 33) | 25 (21, 31.5)/23 (19, 32.25) | U=0.42/−1.14 | 0.673/0.253 |
| Medication time, years | 0.71 (0.11, 2.54)/0.06 (0, 0.87) | 0.16 (0.01, 1.88)/0.25 (0.01, 1.07) | U=−2.76/1.33 | 0.006*/0.184 |
| Body mass index, kg/m2 | 23.48 (3.70)/23.52 (4.35) | 24.38 (4.72)/22.43 (3.46) | t=1.24/1.59 | 0.214/0.117 |
| Dose, mg/day | 4.55 (4, 6)/14.25 (10, 20) | 3.72 (2, 4.75)/11.89 (5, 16.25) | U=−3.73/−2.31 | <0.001**/0.021* |
| Fasting plasma glucose, mmol/L | 5.14 (4.75, 5.42)/4.87 (4.34, 5.30) | 5.28 (4.80, 5.84)/5.10 (4.70, 5.43) | U=1.75/2.29 | 0.080/0.022* |
| Total cholesterol, mmol/L | 4.51 (0.92)/4.62 (0.94) | 4.49 (0.90)/4.53 (0.93) | t=0.183/0.628 | 0.860/0.531 |
| Triglycerides, mmol/L | 1.17 (0.77, 1.45)/1.26 (0.72, 1.92) | 1.37 (0.89, 1.94)/1.36 (0.94, 1.87) | U=2.76/0.68 | 0.006*/0.499 |
| PRL, ng/mL | 59.01 (41.36, 93.15)/52.27 (39.0, 95.87) | 11.70 (3.15, 18.59)/12.78 (5.12, 18.57) | —— | —— |
Normal distribution (mean+SD).
Non-normal distribution (median (Q1, Q3)).
*p≤0.05
**p≤0.001
OLZ, olanzapine; PRL, prolactin; RIS, risperidone.